Evotec SE
XETRA:EVT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.265
21.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Evotec SE
Other Current Liabilities
Evotec SE
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Evotec SE
XETRA:EVT
|
Other Current Liabilities
€210.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
36%
|
|
|
Gerresheimer AG
XETRA:GXI
|
Other Current Liabilities
€167.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
0%
|
|
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
Other Current Liabilities
€192.6m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Evotec SE
Glance View
Nestled within Germany's innovation-focused sector, Evotec SE has carved a niche for itself as a leading player in the field of drug discovery and development solutions. From its inception, Evotec has thrived on its commitment to delivering comprehensive solutions that expedite the journey from conceptualization to clinical success. At the core of its business model is a robust and scalable platform approach, which integrates cutting-edge technologies such as high-throughput screening, phenotypic screening, and computational biology. By leveraging these advanced methodologies, Evotec collaborates with pharmaceutical giants, biotech firms, and academic institutions, offering them customized services and shared-risk alliances. This symbiotic partnership model not only accelerates drug discovery but also minimizes the resource constraints typically associated with early-stage research. Evotec's revenue generation is intricately tied to its partnerships and collaborations, which involve milestone and royalty payments, alongside direct service fees. Its business strategy is propelled by a unique combination of proprietary drug development initiatives and strategic collaborative ventures. This dual-pronged approach allows Evotec to share the financial risk of drug development while maintaining potential upside through successful compounds. Moreover, the company's proactive investments in its own pipeline complement the service-based revenue, as they position Evotec to capture significant gains from future licensing or the eventual commercialization of internally researched drugs. With a strong emphasis on scientific excellence and commercial viability, Evotec meticulously balances innovation with strategic foresight, crafting a sustainable business that stands resilient amid the ever-evolving pharmaceutical landscape.
See Also
What is Evotec SE's Other Current Liabilities?
Other Current Liabilities
210.2m
EUR
Based on the financial report for Sep 30, 2024, Evotec SE's Other Current Liabilities amounts to 210.2m EUR.
What is Evotec SE's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
36%
Over the last year, the Other Current Liabilities growth was 9%. The average annual Other Current Liabilities growth rates for Evotec SE have been 12% over the past three years , 18% over the past five years , and 36% over the past ten years .
You don't have any saved screeners yet
